Drug intelligence / Profile preview

erlotinib + capmatinib + enfortumab vedotin (Roche)

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Oral, Intravenous

Overview

This combination regimen consists of erlotinib (Tarceva), capmatinib (Tabrecta), and enfortumab vedotin (Padcev). Erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). Capmatinib is a selective inhibitor of the MET receptor tyrosine kinase. Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, which delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE) directly to cancer cells. This specific combination is being evaluated in a personalized medicine context, such as the iCAGES-guided therapy study (NCT03535623), where treatments are selected based on the genomic and immunohistochemical profile of a patient's tumor to improve survival outcomes in advanced cancers.

Brand names: Tabrecta
Other names: Tarceva + capmatinib + Padcev

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)MET (Mesenchymal-epithelial transition factor receptor)PVRL4 (Nectin cell adhesion molecule 4)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on erlotinib + capmatinib + enfortumab vedotin (Roche).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + capmatinib + enfortumab vedotin (Roche).

Explore the full profile